• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RAD
Click for more information
2.98% 16.3¢

Radius Residential Care Limited Ordinary Shares

watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
RAD
Ann: Radius Care: Strategic Growth Acquisition - Cibus Catering 		07/10/24 0 19
07/10/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  19 
RAD
Ann: Capital Change Notice - 10-year employee share scheme 		21/08/24 0 68
21/08/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  68 
RAD
Ann: Amended Annual Meeting Results 		09:11 0 61
09:11 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  61 
RAD
Ann: Results of Annual Shareholders' Meeting 2024 		06/08/24 0 55
06/08/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  55 
RAD
Ann: Update on 1QFY25 and Annual Meeting Materials 		06/08/24 0 85
06/08/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  85 
RAD
Ann: Climate-Related Disclosures Report 2024 		26/07/24 0 67
26/07/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  67 
RAD
Ann: Ongoing Disclosure Notice 		11/07/24 0 86
11/07/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  86 
RAD
Ann: Notice of Annual Meeting 		05/07/24 0 131
05/07/24 Last post  NZX News Comments Created with Sketch.  0  Views Created with Sketch.  131 

See All Discussions arrow Created with Sketch.

Featured News

NEWS High-grade gold discovery at Didievi Project: First drill results reveal impressive 33m intercept at 2.4g/t
right-arrow Created with Sketch.
NEWS Exciting new copper-gold discoveries at Tarraji-Yampi: Dive into the strong drilling results now
right-arrow Created with Sketch.
NEWS Waroona Project financing strategy aims for non-dilutive funding solutions - discover how this approach will support its Stage One development
right-arrow Created with Sketch.
NEWS See what company has secured $98M, 8-year contract renewal with Mercy Health
right-arrow Created with Sketch.
NEWS Significant increase in revenue from faster NDIS approvals and launch of new leasing programs
right-arrow Created with Sketch.
NEWS Second consecutive quarter of record revenue driven by strong sales growth in market-leading medical products!
right-arrow Created with Sketch.
(20min delay)
Last
16.3¢ 		Change
-0.005(2.98%) 		Mkt cap ! n/a
Open High Low Value Volume
16.6¢ 16.6¢ 16.3¢ $20.8K 127.2K

Buyers (Bids)

No. Vol. Price($)
0 6901 16.0¢
 

Sellers (Offers)

Price($) Vol. No.
16.3¢ 69374 0
Last trade - 13.00pm 07/10/2024 (20 minute delay) ?
RAD (NZSX) Chart

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03 Nyrada Inc has completed an in-vivo micronucleus on the effects of its NYR-BI03 drug on rats, suggesting it causes no genetic damage
Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program Arika Resources Ltd has received commitments from investors in support of a Placement worth $3.2 million to support gold exploration in WA
Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.

Featured News

NEWS Antler Copper Project hits major permitting milestone – air quality permit advances to final review
right-arrow Created with Sketch.
NEWS See what company has secured $98M, 8-year contract renewal with Mercy Health
right-arrow Created with Sketch.
NEWS Most viewed thread today: Rio Tinto confirms approach to Arcadium Lithium
right-arrow Created with Sketch.
LU7 Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
right-arrow Created with Sketch.
NEWS Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03
right-arrow Created with Sketch.
NEWS Step out drilling confirms high-grade cobalt & associated copper at Bald Hill
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.